New weight-loss drug sails through all-important Phase III trial
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, with nearly 90% of participants losing at least 5% of their body weight. The results strengthen its case for US Food and Drug Administration approval.
Category: Obesity, Illnesses and conditions, Body & Mind
Tags: Peking University, Ozempic, Weight Loss, GLP-1 receptor agonists, clinical trials, Obesity, Diabetes, Health